MenAfriVac

Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award

Retrieved on: 
星期五, 四月 19, 2024

Fueled by an early interest in science as a child in South Africa -- in part due to a physician father – Klugman holds both a medical as well as a science doctorate degree from Wits University and was the first student in the school’s history to obtain them simultaneously. He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist. Klugman is widely known for his work on pneumonia, which still kills a child under five every 43 seconds, many in the world’s poorest countries. As the director of the pneumonia program at the Seattle-based Bill and Melinda Gates Foundation, Klugman orchestrates strategic initiatives aimed at reducing deaths from pneumonia, RSV, neonatal sepsis, and meningitis. He has authored hundreds of publications that have been cited over 50,000 times to date and has been elected to the National Academy of Medicine in the United States. Klugman is also a professor emeritus of global health at Atlanta’s Emory University.

Key Points: 
  • Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute.
  • He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist.
  • His scientific achievements aside, Klugman has long championed the need for the world’s poorest children to have equitable access to vaccines.
  • Sabin’s Rising Star award was created in 2020 to encourage and recognize the next generation of vaccine and immunization leaders.

Outlook on the Meningococcal Vaccines Global Market to 2030 - Increasing Immunization Programs and Government Initiatives is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
星期二, 六月 14, 2022

The global meningococcal vaccines market size is expected to reach USD 4.92 billion by 2030, registering a CAGR of 6.2%.

Key Points: 
  • The global meningococcal vaccines market size is expected to reach USD 4.92 billion by 2030, registering a CAGR of 6.2%.
  • In addition, rising FDA approval for meningococcal vaccines is expected to boost the growth.
  • The increase in approval of novel vaccines is expected to improve meningococcal prevention which in turn, is anticipated to drive the market.
  • Initiatives undertaken by the government to combat the rising incidence of the disease are anticipated to boost the meningococcal vaccine market growth.

Meningitis Canada Calls on Governments to Fund Meningitis B Vaccine

Retrieved on: 
星期一, 六月 28, 2021

WATERLOO, Ontario, June 28, 2021 (GLOBE NEWSWIRE) -- In the wake of the tragic death of 19-year-old Kai Matthews of Halifax, Nova Scotia, Meningitis Foundation Canada (MFC) calls on all Canadian provinces and territories to include meningitis B on their routine immunization schedules.

Key Points: 
  • WATERLOO, Ontario, June 28, 2021 (GLOBE NEWSWIRE) -- In the wake of the tragic death of 19-year-old Kai Matthews of Halifax, Nova Scotia, Meningitis Foundation Canada (MFC) calls on all Canadian provinces and territories to include meningitis B on their routine immunization schedules.
  • Despite being approved, many young Canadians and their families are not aware of the meningitis B vaccines and therefore have not been immunized.
  • If the COVID-19 pandemic has taught us anything, it has driven home the cold hard fact that vaccine prevention saves lives.
  • For more information on meningitis and how to protect against this deadly disease, visit www.meningitis.ca or Join Us on Facebook , Twitter and Instagram .

Insights on the Meningococcal Vaccine Global Market to 2026 - Featuring GlaxoSmithKline, Pfizer and Sanofi Among Others

Retrieved on: 
星期二, 四月 20, 2021

In meningococcal meningitis, bacteria infect the lining of the brain and spinal cord and can potentially cause large endemics as well as epidemics.

Key Points: 
  • In meningococcal meningitis, bacteria infect the lining of the brain and spinal cord and can potentially cause large endemics as well as epidemics.
  • According to the Centers for Disease Control and Prevention (CDC), about 1.2 million cases of meningococcal meningitis are estimated to occur worldwide every year.
  • The government and regulatory authorities are taking initiatives to combat the increasing prevalence of meningitis are likely to drive the market growth.
  • North America led the market and had a significant revenue share of the market in 2019 which is followed by Europe.

Meningococcal Vaccine Market to Reach $4.19 Bn, Globally, by 2026 at 9.5% CAGR: AMR

Retrieved on: 
星期二, 五月 19, 2020

According tothe report, the global meningococcal vaccine industry generated $1.93 billion in 2018, and is estimated to reach $4.19 billion by 2026, growing at a CAGR of 9.5% from 2019 to 2026.

Key Points: 
  • According tothe report, the global meningococcal vaccine industry generated $1.93 billion in 2018, and is estimated to reach $4.19 billion by 2026, growing at a CAGR of 9.5% from 2019 to 2026.
  • Rise in outbreaks of meningococcal disease, increase in immunization programs across the world, and surge in research and development for vaccine technology drive the global meningococcal vaccine market.
  • However, long duration required for vaccine production and high cost of vaccine development hinder the market growth.
  • Based on vaccine type, the conjugate segment held the largest share of the global meningococcal vaccine market, accounting for nearly half of the total market share in 2018, and is estimated to maintain its lead by 2026.

Meningococcal Vaccine Market to Reach $4.19 Bn, Globally, by 2026 at 9.5% CAGR: AMR

Retrieved on: 
星期二, 五月 19, 2020

According tothe report, the global meningococcal vaccine industry generated $1.93 billion in 2018, and is estimated to reach $4.19 billion by 2026, growing at a CAGR of 9.5% from 2019 to 2026.

Key Points: 
  • According tothe report, the global meningococcal vaccine industry generated $1.93 billion in 2018, and is estimated to reach $4.19 billion by 2026, growing at a CAGR of 9.5% from 2019 to 2026.
  • Rise in outbreaks of meningococcal disease, increase in immunization programs across the world, and surge in research and development for vaccine technology drive the global meningococcal vaccine market.
  • However, long duration required for vaccine production and high cost of vaccine development hinder the market growth.
  • Meningococcal vaccine is used as a placebo effect in the Covid-19 vaccine trial conducted at the University of Oxford.

National Meningitis Association Urges Parents to Get Their Teens The 16 Vaccine to Help Protect Against Meningococcal Meningitis

Retrieved on: 
星期一, 九月 17, 2018

The 16 Vaccine ( The16Vaccine.org ) aims to educate parents about the importance of this critical second dose of MenACWY, which helps protect teens against meningococcal meningitis during the period when they are at increased risk.

Key Points: 
  • The 16 Vaccine ( The16Vaccine.org ) aims to educate parents about the importance of this critical second dose of MenACWY, which helps protect teens against meningococcal meningitis during the period when they are at increased risk.
  • "Some parents are aware of the primary dose of MenACWY vaccine at 11-12 years of age, but they don't know CDC recommends a second dose at age 16.
  • The campaign website features emotional firsthand stories of meningococcal meningitis survivors and advocates whose lives have been irrevocably impacted by the disease.
  • Parents can also sign up for a text reminder at The16Vaccine.org, which will alert parents when it's time to schedule an appointment for their teen's 16-year vaccine visit.